Arcutis begins Phase 3 trial of Zoryve cream 0.3% for moderate to severe atopic dermatitis
ARQT•Arcutis Biotherapeutics enrolled the first participant in its Phase 3 INTEGUMENT-3 trial of once-daily Zoryve cream 0.3% for patients ages 6 and older with moderate to severe atopic dermatitis.
1. Trial enrollment begins
The Phase 3 INTEGUMENT-3 trial will evaluate the efficacy, safety and tolerability of once-daily roflumilast cream 0.3% in patients ages 6 and older with moderate to severe atopic dermatitis. Results have not yet been presented.
